Following the screening of a 900-compound pretomanid analogue library, several hits with more suitable potency, solubility, and microsomal stability were identified, and the superior efficacy of newly synthesized 6R enantiomers with phenylpyridine-based side chains was established through head-to-head assessments in a Leishmania donovani mouse model. Two such leads (R-84 and R-89) displayed promising activity in the more stringent Leishmania infantum hamster model but were unexpectedly found to be potent inhibitors of hERG. An extensive structure−activity relationship investigation pinpointed two compounds (R-6 and pyridine R-136) with better solubility and pharmacokinetic properties that also provided excellent oral efficacy in the same hamster model (>97% parasite clearance at 25 mg/kg, twice daily) and exhibited minimal hERG inhibition. Additional profiling earmarked R-6 as the favored backup development candidate.
■ INTRODUCTION
Visceral leishmaniasis (VL) is a particularly lethal sandfly-borne parasitic disease that is prevalent in more than 60 countries, where it mostly affects underprivileged people in remote rural areas who have limited access to diagnosis and treatment. 1−3 Major outbreaks of VL in East Africa have been attributed to waves of forced migration during periods of conflict, and such epidemics are exacerbated by weak healthcare systems, malnutrition, and HIV/AIDS coinfection. 4, 5 Moreover, in this region, the first-line drug combination of paromomycin and sodium stibogluconate was found to be unsuitable for VL patients who were >50 years of age or those with HIV, and no other therapies have shown adequate efficacy. 6, 7 Failure of the most recently evaluated new agent, fexinidazole, in a phase II clinical trial for VL in Sudan 8 has now left the clinical pipeline empty, underlining the compelling need to develop more satisfactory medications. 9 The target product profile (TPP) of an optimized new chemical entity for the treatment of VL requires (i) effectiveness against all causative species, in all endemic areas, in both immunocompetent and immunosuppressed individuals, with a clinical efficacy of >95%; (ii) activity against resistant strains; (iii) no adverse safety events requiring monitoring and no contraindications; (iv) no drug−drug interactions (suitable for combination therapy); (v) oral administration once per day for a maximum of 10 days (or intramuscular dosing three times over 10 days); (vi) stability in relevant climates (3 years); and (vii) affordable cost (<$80, ideally <$10 per course). 10 However, new drug discovery for VL faces formidable challenges, such as inadequate investment, a lack of validated targets, poor translation of in vitro activity into in vivo models, and meager hit rates (<0.1%) for phenotypic screening of compound libraries.
11 −13 The latter may be due in part to the concealed location of parasites in acidic parasitophorous vacuoles within macrophages.
14 Furthermore, the unique glycolipid-rich cell surface of the amastigotes presents an additional barrier to chemotherapy. 15 Another issue is that many cellularly active hits may never meet TPP and progression criteria, even after valiant optimization attempts. 13, 16 Nevertheless, drug development efforts spearheaded by the Drugs for Neglected Diseases initiative (DNDi) have now shown encouraging progress in several novel classes, including oxaboroles and aminopyrazoles. 12, 17, 18 Novartis has also disclosed a triazolopyrimidine preclinical lead with utility in vivo against both leishmanial and trypanosomal infections. 19 The 2-nitroimidazooxazines are best known for their potent effects against Mycobacterium tuberculosis (M. tb), the causative agent of tuberculosis (TB). 20 The first drug candidate from this class, pretomanid [PA-824, S-1 ( Figure 1 )], has shown excellent safety and bactericidal efficacy in phase II clinical trials for TB, 21 leading to its ongoing combination assessment, 22 while our collaborative work with the TB Alliance on second-generation analogues of S-1 culminated in the advancement of TBA-354 (S-2) into phase I studies. 23 We have recently described the investigation of a novel 7-substituted 2-nitroimidazooxazine class, which in addition to possessing considerable potential against TB has also demonstrated exciting activity against both VL and Chagas disease, resulting in the selection of preclinical VL lead 3. 24 This followed an indepth analysis of the structurally related 6-nitroimidazooxazole class, 25 where phenotypic screening of some of our initial examples by DNDi had enabled the discovery of previous development nominee 4 (DNDI-VL-2098). 26 The latter was found 27 to be activated by a novel leishmanial nitroreductase (NTR2). In comparison to 4, candidate 3 exhibited an improved safety profile and had similarly notable efficacy in two animal models of VL. 24 Furthermore, while the new TB drug delamanid (5) has also been suggested as a possible VL therapy, 28 it is noteworthy that 3 was substantially more effective than this agent in the highly stringent chronic infection hamster model. 24, 25 As part of our VL lead optimization program with DNDi, it was considered important to develop a few efficacious backup compounds having good physicochemical/pharmacological profiles and better safety, to mitigate development risks. Given the encouraging results with nitroimidazooxazoles and 7-substituted 2-nitroimidazooxazines, we first evaluated various other pretomanid-related scaffolds for VL, including those with a reversed linker at C- 6 29,30 and novel nitroimidazooxazepines. We then assessed our larger collection of pretomanid analogues via the medium-throughput screening of ∼900 compounds at the Institut Pasteur Korea (IPK). Finally, a more systematic synthetic approach was employed to redevelop the 6-substituted 2-nitroimidazooxazine class for VL, taking into consideration both enantiomer forms. We now report the findings from these wide-ranging structure−activity relationship (SAR) studies, including the detailed in vitro/in vivo profiling of selected new leads, which resulted in our identification of the title compound as a very promising VL backup candidate.
■ CHEMISTRY Scheme 1 outlines the synthetic methods used to prepare eight novel racemic analogues of S-1 featuring changes to the original nitroimidazooxazine core (14, 22, 23, 32, 33, 39, 40, and 47) . A common strategy (based on the original, well-validated route to S-1 and simple derivatives) 31, 32 proved to be effective for the first five of these (Scheme 1A−C), involving the initial reaction of functionalized epoxides (9, 33 17, and 27 34 ) with 2,4-dinitroimidazole (8), followed by THP protection of the derived alcohols (10, 18, and 28). In the shorter chain cases (11 and 19) , subsequent cleavage of the TBS ether (TBAF) enabled in situ annulation, whereas in the latter instance (29) , oxazepine ring formation required additional treatment with a strong base (NaH). Removal of the THP group with methanesulfonic acid and standard alkylation chemistry on alcohols 13, 21, and 31 then gave the aforementioned targets.
For the isomeric oxazepines (Scheme 1D), THP protection of alcohol 34 24 and desilylation (TBAF) similarly furnished the noncyclized alcohol 36, which was ring-closed (NaH and DMF) and THP-deprotected (HCl) to produce alcohol 38. However, both final step alkylations of 38 unexpectedly cogenerated significant quantities (20−36%) of the isomeric 7-substituted oxazine derivative (41 or 42) , together with the desired oxazepine ether (39 or 40) . Although this is unconfirmed, it is postulated that this rearrangement may involve an intramolecular S N Ar reaction, with attack by the oxazepine alkoxide anion at the imidazole ring junction carbon 9a and subsequent alkylation of the released 2-nitroimidazooxazine 7-alkoxide (but it should be emphasized that no similar rearrangements were detected during the derivatization of 13, 21, 31, or the alcohol precursor to S-1, and that S-1 itself has shown excellent safety and a lengthy 16−18 h half-life in clinical trials for TB, 35 suggesting that 2-nitroimidazooxazine-based VL leads would be unlikely to demonstrate an excessive reactivity toward biological nucleophiles; this is further supported by an observed tolerance of the latter ring system toward several basic nucleophiles in the chemistry reported below). The remaining 
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Article scaffold, nitrotriazolooxazine 47, was accessed from 5-bromo-3-nitro-1,2,4-triazole (43) and iodide 44, 36 via desilylation/in situ annulation of the major adduct 46, as shown above (Scheme 1E).
The assembly of new biaryl and heterobiaryl side chain variants of S-1 and its enantiomer, R-1, 37, 38 was relatively straightforward (Schemes 2 and 3). Biphenyl analogues (R-58, R-60, and R-62) were created by Suzuki coupling reactions on halobenzyl ether derivatives of the key 6-R alcohol 56, 32 while combination of 56 with bromide 63 39 afforded the terminal pyridine R-64 (Scheme 2A). Alternative alkylation of 56 or its 6-S equivalent 65 32 with various isomeric bromomethyl bromopyridines (66, 71, 75, 82, 39 and 97) then set up the Suzuki-based manufacture of novel ortho-linked phenylpyridines [S-69, R-69, S-74, and R-74 (Scheme 2B,C)] and both meta-and para-linked congeners (Schemes 2D and 3A,C). This latter work was further expanded to include examples containing a pyridazine, pyrazine, or pyrimidine ring (R-109, R-112, and R-115), using similar chemistry 39 (Scheme 3D), and to a novel racemic nitrotriazole counterpart of R-84 [88 (Scheme 3B)], starting from alcohol 86. 40 Lastly, a buffered m-CPBA oxidation of R-84 supplied pyridine N-oxide R-85 (Scheme 3A).
Several reference benzyl ethers (R-1, 38 R-7, 32 R-118, and R-119) were sourced through direct alkylations of 6-R alcohol 56 32 (Scheme 4A). Three extended ether targets (R-122, R-123, and R-124) were also formed by Sonogashira reactions on the propargyl ether R-121, derived from the coupling of 56 with bromide 120. 41 Next, the orthogonally diprotected triol 125 42 was employed in complementary syntheses of the novel R and S enantiomers of racemic ether 6 42 (Scheme 4B,C). Following a Mitsunobu reaction of 125 with 4-(trifluoromethoxy)phenol, selective removal of the PMB group (DDQ), iodination of the resulting alcohol 127, and reaction with 2-bromo-4-nitroimidazole (129) gave silyl ether 130. Treatment of the latter with TBAF and sodium hydrideinduced ring closure then produced S-6. Conversely, successive cleavage of the TIPS group from 126, iodination, and then reaction with 129 provided PMB ether 134. Oxidative debenzylation of 134 with DDQ in the absence of water unexpectedly led to partial acetalization of the alcohol product with 4-methoxybenzaldehyde, but this mixture was cleanly converted back to 135 via acid hydrolysis (TsOH/MeOH). Base-assisted annulation of alcohol 135 (NaH) then furnished the second enantiomer, R-6. In subsequent work, 2-pyridinyl ether analogues of both R-6 (R-136, R-137, and R-138) and triazole 47 (139) were accessed from alcohols 56 32 and 86, 40 respectively, via sodium hydride-catalyzed S N Ar displacement reactions on halopyridines (Scheme 4D), while Cu(I)-induced coupling of 56 with aryl isocyanates generated the Ocarbamates R-140 and R-141 (Scheme 4E). Finally, piperazine carbamate R-143 was synthesized by chloroformylation of alcohol 56 and in situ reaction with 1-[4-(trifluoromethoxy)-phenyl]piperazine 43 (142) (Scheme 4F). Further linker diversity was accessed through the transformation of 6-S alcohol 65 32 into the novel 6-R amine hydrochloride, 146 (Scheme 5A). Following tosylation of 65 and azide displacement, reduction of 6-R azide 145 with propane-1,3-dithiol gave the required amine, which was converted to its hydrochloride salt for improved stability. From this intermediate, reductive alkylation with benzaldehydes (using NaBH 3 CN), acylation with benzoyl chlorides, or treatment with phenyl isocyanates in the presence of catalytic dibutyltin diacetate yielded the expected benzylamine, benzamide, or phenyl urea derivatives (Scheme 5A,B). Then, to conclude this study, a variety of shorter O-linked heterobiaryl side chains were constructed using Suzuki couplings on haloheteroaryl ether precursors [156, 159, 167, 170, and 173 (Scheme 5C−E)]. The latter were obtained directly from alcohol 56, via S N Ar reactions on fluoropyridines or chloropyrimidines, or, in the case of 167, from the diprotected triol 125 42 and 6-bromopyridin-3-ol, using the same methodology as described above for R-6.
■ RESULTS AND DISCUSSION
To establish the SARs against kinetoplastid diseases, 76 new (and several known) pretomanid analogues derived from successive projects with TB Alliance and DNDi were retrospectively tested in replicate assays conducted at the University of Antwerp [LMPH (Tables 1−4) ]. These assays measured activity versus the intracellular amastigote forms of both Leishmania infantum (L. inf) and Trypanosoma cruzi (T. cruzi) and against the bloodstream form of Trypanosoma brucei (T. brucei); cytotoxicity toward human lung fibroblasts (MRC-5 cells, the host for T. cruzi) was also assessed. 44 Much of our VL lead optimization work with DNDi was earlier guided by the findings from single IC 50 determinations against Leishmania donovani (L. don) in a mouse macrophage-based luciferase assay 26 performed at the Central Drug Research Institute (CDRI, Pradesh, India), and by follow-up evaluations of in vitro microsomal stability and efficacy in the mouse VL model (Figure 2A ). The best leads were then advanced to further appraisal in the more stringent hamster VL model. Overall, while excellent in vivo efficacy was a key goal for secondgeneration VL drug candidates, we also aspired (a) to minimize compound lipophilicity (estimated using ACD LogP/LogD software, version 14.04, Advanced Chemistry Development Inc., Toronto, ON) to lessen toxicity risks, (b) to increase aqueous solubility (as judged by kinetic data on dry powder forms of active leads) for optimal oral bioavailability, and (c) to reduce hERG inhibition potential (cf. 4) 24 to improve safety. Scaffold Modification: Initial Hits. As part of our earlier TB studies, we had examined some fundamental changes to the nitroimidazooxazine "warhead", including replacement of the nitroimidazole ring by nitropyrazole or nitrotriazole [e.g., 48-50 (Table 1) ] and exchange of the 8-oxygen for sulfur or nitrogen. 40 We had also explored reversal of the C-6 linker (e.g., 24−26) 29, 30 and transposition of the side chain to position 7 (e.g., 41 and 42). 24 In a further extension to this work (seeking improved metabolic stability and new active 
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Article scaffolds), the novel methylated derivatives 14, 22, and 23 were investigated, together with nitroimidazooxazepines 32, 33, 39, and 40. Unfortunately, except for the 7,7-dimethyl derivative 22 [which showed antitubercular potency comparable to that of 1 and excellent stability toward human liver microsomes, HLM, 92% after 1 h (Table 5) ], these compounds proved to be unattractive for TB. Nevertheless, in preliminary antiparasitic screening at the Swiss Tropical Institute, 23, 25, and 26 demonstrated encouraging utility against L. don in a mouse macrophage assay (IC 50 s of 1.2−1.5 μM), 29 and triazole 49 exhibited striking activity versus Chagas disease (T. cruzi IC 50 of 0.084 μM). For greater clarity, we will focus the discussion first on the intended main application (VL) and discuss the other parasite data in a closing section. Follow-up testing of a larger set of compounds at CDRI 26 identified 1, 6, 24, and 40 as being superior for VL [L. don IC 50 s of 0.26−0.46 μM (Table 1) ], although such hits were still an order of magnitude less potent than 4 and the 7-substituted oxazine 41 (IC 50 s of 0.03 μM).
24,25
These results, together with evidence of the reduced solubility and more rapid metabolism of analogues with 4-benzyloxybenzyl side chains, 36, 42 prompted the further appraisal of 24 in an L. don infection VL mouse model. Disappointingly, 24 displayed weak activity [31% inhibition at 25 mg/kg, dosing po daily for 5 days (Table 5) ], despite its reasonable mouse PK profile [50% oral bioavailability, moderate exposure, and 2 h half-life (Table 6) ]. This outcome implied the need to significantly boost in vitro potencies in this class. However, two highly effective phenylpyridine analogues of 24, 116 30 and 117 30 [L. don IC 50 s of 0.02−0.05 μM (Table 2) ], also failed to deliver useful activity in this in vivo assay under the same dosing regimen (23−49% inhibition). Analysis of their mouse PK data identified low oral bioavailability (11−15%) as a contributing factor here because greater oral exposure led to better efficacy [116 (Table 6 and Figure S1 )]. A related concern for both compounds was poor aqueous solubility [0.13−0.27 μg/mL at pH 7 (Table 5) ], while retrospective testing against L. inf later revealed suboptimal potency (IC 50 s of ∼6 μM). Taken together, these findings reinforced the importance of improving both potency and in vivo PK properties, to achieve suitable efficacy in VL models. To this end, we returned to our sizable pretomanid analogue library, where we had already amassed key solubility and DMPK information from extensive earlier studies with the TB Alliance. Library Screening and Hit to Lead Assessments for VL. To assist the identification of more active leads from the 6-substituted nitroimidazooxazine class, an 898-member library was screened against L. don amastigotes in a seven-point 3-fold dilution macrophage assay at the Institut Pasteur Korea (mid-2010). 45 In total, 248 compounds (28%) showed >50% inhibition at 10 μg/mL, although only 89 (36%) of these displayed >50% inhibition at 3.3 μg/mL, and known actives from the nitroimidazooxazole and 7-substituted oxazine classes were dispersed across both groupings. By eliminating examples from previously inspected classes (including the "reversed C-6 linker" series above), we obtained a starting set of 169 hits. This set was further refined by excluding compounds with a higher propensity for metabolic and/or solubility issues, based on established trends, to give 42 hits, which were retested at CDRI.
Scheme 3 a
The most relevant results are summarized in Figure 3 , with almost all of the remaining hits manifesting weaker potencies (L. don IC 50 s of 0.5−11 μM). We also screened S-1 and S-2, but both had only modest activities (L. don IC 50 s of 3.9 and 2.6 μM, respectively). Nevertheless, in view of the 10-fold higher potency of racemic 1 [IC 50 of 0.39 μM (Table 1) ], this result for S-1 was highly significant as it implied that 6R enantiomers (which have little activity against M. tb 32,37 ) may be the more active chiral form for VL. Therefore, we synthesized a trial set of 10 compounds (R-1, R-2, R-7, R-58, R-60, R-62, R-77, R-81, R-84, and R-94) for assessment. In 9 of 10 cases, these 6R enantiomers exhibited 1.1−12-fold superior potencies [L. don IC 50 s of 0.06−1.4 μM (see Tables S2 and S3) ]; hence, the 6R counterparts of selected hits in Figure 3 were also targeted (in line with the approach in Figure 2A) .
In an effort to further prioritize the library screening hits for in vivo evaluation, five compounds of high lipophilicity (CLogP > 4 for S-53, 46 S-54, 30 S-55, 47 S-58, 47 and S-64 39 ) were omitted from further study and the remaining 12 were assessed for aqueous solubility and microsomal stability (Table 5 and cited references for Figure 3 ). Both the amide S-151 48 and urea S-155 provided encouraging solubility data (132 and 22 μg/mL, respectively), but the urea unexpectedly showed poor stability toward mouse liver microsomes (MLM, 43% parent after 30 min). Conversely, both the lipophilic arylthiazole S-51 49 (CLogP ∼ 4.0) and the arylpyrimidine S-171 42 were considered of borderline interest because of their modest solubility values (0.9−1.6 μg/mL). While some phenylpyridine hits (e.g., S-77, S-89, S-91, S-92, and S-99) 39 were not substantially more soluble than this at pH 7 (1.4−4.0 μg/mL), these compounds have demonstrated greatly superior results at pH 1 (211−1780 μg/mL). It has been recognized that the low pH of gastric fluid (typically ∼1−2) can enhance the dissolution and oral absorption of such weak bases. 50 Furthermore, close analogue S-2 was advanced to clinical studies for TB partly on the basis of its superior in vivo PK properties in comparison to those of delamanid (5) , which are absorption-limited. 23 Concordant with this, the most potent phenylpyridine hits in Figure 3 (S-77, S-81, S-89, S-91, and S-92) also displayed broadly acceptable HLM and MLM stabilities (>70% remaining after 30 min), suggesting their suitability for in vivo studies.
The best six screening hits mentioned above (phenylpyridines S-77, S-81, S-89, S-91, and S-92 and amide S-151) were then evaluated in the mouse VL model alongside a similar set of 6R enantiomers (R-77, R-84, R-89, R-91, R-92, R-94, and R-151), dosing at 50 mg/kg orally, once daily for 5 days. Results for the meta-linked phenylpyridines R-77, S-77, and S-81 were not particularly impressive [52, 44 , and 35% inhibition, (Table 5) ], although the level of activity did track with their respective L. don IC 50 s (0.06, 0.12, and 0.24 μM, respectively). In contrast, pairwise comparison of para-linked phenylpyridines S-89, S-91, and S-92 with their 6R counterparts unequivocally confirmed the latter as being superior [R-89 (99.5%) vs S-89 (45%), R-91 (99.8%) vs S-91 (69%), and R-92 (94%) vs S-92 (37%)], notwithstanding their slightly higher rates of metabolism (e.g., R-91, 81% parent after 30 min in MLM, vs S-91, 100%). In this series, the 4-fluoro analogue R-94 (L. don IC 50 of 0.18 μM) showed reduced utility (83%), whereas the apparently less potent 4-trifluoromethoxy congener R-84 (IC 50 of 0.32 μM in the same CDRI assay) provided excellent efficacy (99.4%), despite having lower microsomal stability (36% vs 66% after 1 h in MLM). Overall, the most effective (6S) screening hit was the soluble amide S-151 (72%), but its 6R form (R-151) was unexpectedly poor (5%). However, for this 6-N-linked benzamide class, it was later discovered that the 6S enantiomers had the stronger in vitro potencies (e.g., L. inf IC 50 s of 5.6 and 12 μM for S-151 and R-151, respectively), suggesting the need for a more systematic investigation of the SAR ( Figure 2B ). For better clarity, we will describe this analysis next, before summarizing the results from additional in vivo assessments on all of the most active new VL leads.
SAR of 6-Substituted 2-Nitroimidazooxazines for VL.
Following the discovery that many 6R enantiomers had superior in vitro and in vivo activities against VL, a more extensive lead optimization study was initiated to develop additional backup candidates to 4 possessing an advantageous solubility, PK−PD, and safety profile. In light of the high potency of ortho-linked biphenyl hit S-58 (L. don IC 50 0.18 μM), we first sought to establish the optimal linking position for biaryl side chains. Comparison of R-58, R-60, and R-62 in both L. don and L. inf assays ( Table 2 ) unexpectedly indicated that ortho linkage was most preferred and that para linkage was least preferred. Therefore, the novel ortho-linked phenylpyridines S-69, R-69, S-74, and R-74 were studied. Here, R-69 and R-74 were equally best, although 1.8-fold less effective than R-58 (L. inf IC 50 s of 2.0 vs 1.1 μM). Interestingly, these two phenylpyridine isomers showed major differences in both solubility and microsomal stability, with the more soluble R-74 (78 vs 0.51 μg/mL) being metabolized extremely rapidly in all three microsome species [0.1−8% remaining after 1 h (Table  5) ], whereas R-69 was more stable than the para-linked analogue R-84 described above (44% vs 36% after 1 h in MLM).
In the meta-linked phenylpyridine series, two new compounds (R-79 and R-80) having terminal ring substituents 
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Article favored in para-linked isomers described above (2-F, 4-OCF 3 , and 4-OCF 2 H) were marginally more potent than R-77 (4-OCF 3 ) and R-81 (4-F) [L. inf IC 50 s of 0.45 and 0.51 vs 0.63 and 0.73 μM, respectively (Table 2) ]. Here, replacement of the proximal phenyl ring in R-60 by 2-pyridine (R-77) resulted in a 3.7-fold improvement in activity (L. inf IC 50 s of 2.3 and 0.63 μM). This enhancement by 2-pyridine was even more pronounced in the para-linked phenylpyridine series (L. inf IC 50 s of 0.71 and >64 μM for R-84 and R-62, respectively), clarifying that with this heterocycle, ortho linkage was less useful than meta or para linkage. However, in the para-linked set, we considered that the 2′-nitrogen would have less steric protection against oxidation, perhaps accounting for the modest microsomal stabilities of some analogues. Indeed, we could form the N-oxide derivative of R-84 (R-85), which was found to be 2.3-fold less potent (L. inf IC 50 of 1.6 μM). Because microsomal stability varied significantly with the substituents in the terminal ring, we evaluated three new congeners (R-90, 3-F, 4-OCF 3 ; R-93, 4-CF 3 ; R-96, 2,4-diF). The most promising of these was R-96 (L. inf IC 50 of 1.2 μM, activity ∼2-fold weaker than those of early leads R-84, R-89, R-91, and R-92), which exhibited a better stability profile in MLM and HLM [57−59% vs 16−40% for R-84, R-89, and R-91 (Table 5) ].
As suggested by the screening data (Figure 3) , replacement of the proximal phenyl ring in R-62 with 3-pyridine (R-2) was less favorable [L. inf IC 50 of 4.1 μM vs 0.71 μM for R-84 (Table  2) ]. Nevertheless, the 6R enantiomers of two hits (R-99, 2-F, 4-OCF 3 ; R-101, 2-Cl, 4-OCF 3 ) and the novel 2,4-difluoro analogue R-106 all displayed good potencies (L. inf IC 50 s of 1.1, 0.61, and 0.85 μM, respectively) and microsomal stabilities at least comparable to those of their 2-pyridine counterparts, although R-101 was cytotoxic (MRC-5 IC 50 of 17 μM). By extension, we examined three less lipophilic diaza proximal rings (R-109, R-112, and R-115) that had proven to be very effective in our TB studies, 39 but these turned out to be of less interest (L. inf IC 50 s of 1.4−2.8 μM). In summary, several new phenylpyridines provided profiles that were attractive for in vivo evaluation, but we had yet to investigate other linker groups. Therefore, we next turned our attention to simpler monoaryl side chains to explore these changes. For this part of the study, we restricted our focus to linkers that had shown particular promise either in the initial screening (e.g., 6-O, 6-NHCO, and 6-NHCONH) or in our earlier TB work.
Commencing with the enantiomer of pretomanid [R-1, L. inf IC 50 of 4.7 μM (Table 3) ], we found variation of the trifluoromethoxy position identified that ortho substitution was 
Article Table 2 . In Vitro Antiparasitic Activities of 6-OCH 2 /CH 2 O-Linked Biaryl Nitroimidazooxazines 
Article best (R-119, L. inf IC 50 of 1.4 μM), followed by meta substitution (R-118), mimicking findings for biphenyl linkage. Switching to a propargyl ether 42 (R-122) produced much greater activity (L. inf IC 50 of 0.33 μM), which was largely retained in trifluoromethylpyridine replacements for the aryl ring 25 (L. inf IC 50 s of 0.44 and 0.53 μM for R-123 and R-124, respectively). Conversely, removal of the benzylic methylene (R-6) also enabled high potency (L. inf IC 50 of 0.53 μM, L. don IC 50 of 0.19 μM), while critically allowing the retention of good aqueous solubility (12 μg/mL) and high microsomal stability [79−81% parent after 1 h in MLM and HLM (Table 5) ]. Therefore, we similarly investigated trifluoromethylpyridine analogues of R-6 (R-136, R-137, and R-138) and while there was an ∼2-fold loss of activity, R-136 demonstrated a 9-fold 
Article improvement in aqueous solubility (110 μg/mL), together with a slower rate of metabolism (90−92% parent after 1 h in MLM and HLM). However, changing to an O-carbamate linker 48 (R-140, R-141, and R-143) proved to be less satisfactory, with moderate to low potencies observed (L. inf IC 50 s of 2.1−17 μM).
Another option to improve solubility was to replace the ether linkage at C-6 with nitrogen-based linkers. 48 The 6-amino analogue of R-1 (R-147) had a 5-fold better solubility value at pH 7 (84 μg/mL) and was >2000 times more soluble at pH 1. Nevertheless, this compound was less stable toward microsomes (e.g., 61% vs 86% in MLM) and showed 2.6-fold lower activity (L. inf IC 50 of 12 vs 4.7 μM), which was not sufficiently improved by varying the ring substituent position (R-148 and R-149). Alternatively, with a carboxamide or urea linker, the enantiomer preference was reversed, with the original 6S forms (S-150, S-151, S-152, S-154, and S-155) being clearly superior but not particularly potent (L. inf IC 50 s of ∼6−10 μM). Hence, the only compounds with useful antileishmanial activity were ether-linked at C-6, although it was apparent that the original OCH 2 linkage was not optimal and that removal of the benzylic methylene may have metabolic stability and potency advantages. To investigate this further, a small set of O-linked phenylpyridine and phenylpyrimidine derivatives was evaluated (Table 4 ). In the phenylpyridine series (R-157 to R-169), activity against L. inf was similar to or better than that for R-6, with the 3-pyridine isomers preferred (R-168 and R-169, IC 50 s of 0.13−0.20 μM). These latter compounds exhibited microsomal stabilities comparable to those of the parent linker series above, but their solubility values were inferior (0.36−1.2 μg/ mL at pH 7). Finally, contrary to the screening data for S-171, a proximal pyrimidine ring was tolerated only when it was paralinked (R-174 and R-175, L. inf IC 50 s of 0.65−0.83 μM). Generally, potency against L. inf was more discriminating and tended to better correlate with in vivo outcomes. 24, 25 Throughout the course of these studies, 10 more candidates (R-1, R-6, R-69, R-96, R-99, R-106, R-136, R-147, R-168, and R-169) were screened for activity in the mouse VL model at 50 mg/kg [dosing po daily for 5 d (Table 5) ]. The ortho-linked phenylpyridine R-69 was disappointing (20% inhibition), but the new para-linked analogues R-96, R-99, and R-106 displayed high efficacies (91−97%). More heartening still was the fact that shorter chain phenylpyridines R-168 and R-169 gave essentially complete clearance of the parasite infection (99.9%), as did their monoaryl counterparts, R-6 and R-136. However, both R-1 and its amino-linked equivalent R-147 were unsatisfactory (50 and 12%, respectively), consistent with their weaker in vitro potencies. During the concluding stages of this project, Patterson et al. 38 reported that R-1 was a potential oral treatment for VL on the basis of its in vivo activity in a comparable mouse model at a much larger dose of 100 mg/kg twice daily, but it is clear from these results and other studies 24 that R-1 may not be the optimal development candidate.
Additional Assessments To Determine the Best VL Lead. Dose−response experiments on 7 of the 10 best compounds (R-6, R-84, R-89, R-91, R-92, R-96, and R-99) in the mouse VL model yielded ED 50 values of 7.5, 12, 14, 28, 20, 28, and 19 mg/kg, respectively (Table 5 and Figure 4) . The more recent O-linked leads, R-136, R-168, and R-169, were also evaluated at a smaller dose of 6.25 mg/kg and provided parasite burden reductions of 30, 99.7, and 72%, respectively. The most efficacious of these (R-168) produced 84% inhibition at 3.13 mg/kg, representing activity at a level similar to that of 
Article the nitroimidazooxazole 4, 25,26 albeit marginal aqueous solubility (0.85 μM at pH 7) deterred its advanced assessment. Instead, we elected to focus initially on the monoaryl ethers R-6 and R-136, together with phenylpyridines R-84 and R-89, which all produced favorable mouse PK data, including excellent oral exposure levels and half-lives of 6−30 h (Table  6 and Figure S1 ).
The selected candidates were further assessed in the chronic infection hamster model, which is considered the bona fide experimental model for VL because it mimics many features of progressive human disease. 51 Pleasingly, at 50 mg/kg twice daily for 5 days, phenylpyridine R-84 achieved 99.9−100% L. inf clearance in all three target organs, and R-89 was almost as good (Table 7 (Table 6 and Figure S2) ].
To better discriminate among the four preferred candidates, we next considered key safety features, starting with measuring their interactions with the hERG channel. While the monoaryl ethers R-6 and R-136 posed minimal risk (hERG IC 50 s of >30 μM), unfortunately, phenylpyridines R-84 and R-89 both caused potent inhibition (IC 50 s of 0.81 and 0.92 μM, respectively), indicating a strong likelihood of QT prolongation 52 (lead optimization criteria 53, 54 mandate an IC 50 of >10 μM). This outcome was not anticipated, as 6S counterparts had generated much less concern. The two remaining compounds c Dosing was done orally, once daily for 5 days consecutively; data are the mean percentage reduction of parasite burden in the liver.
d Dose in milligrams per kilogram required to achieve a mean 50% reduction in parasite burden.
Article 
Article were then checked for any evidence of mutagenicity in the Ames test. Here, phenyl ether R-6 was negative, but the more soluble pyridinyl ether R-136 unexpectedly yielded a positive result. Although several other nitroimidazole drugs are Ames positive (e.g., metronidazole and fexinidazole), 55 this outcome effectively ruled R-136 out of contention because it would face a more difficult path to achieving regulatory approval. 16, 53 Thus, R-6 was identified as the optimal VL lead.
Further Appraisal of VL lead R-6. Additional properties of R-6 were measured and weighed against those of the initial preclinical candidate 4 ( Table 8 ). The two compounds were comparable in terms of molecular weight (345 Da vs 359 Da) and were both highly permeable, but R-6 had a lower measured LogD value (2.59 vs 3.10 for 4 and 2.52 for S-1 48 ), superior thermodynamic solubility (23 μM vs 2.8 μM), and a reduced propensity to bind to plasma proteins in various species (82− 87% vs 92−96% for 4). This lead also showed only weak CYP3A4 activity (IC 50 > 40 μM) and produced a notably favorable rat PK profile, with prolonged exposure and 100% oral bioavailability (Table 6 and Figure S2 ). These attributes reinforced our conclusion that R-6 (DNDI-8219) was indeed a very promising backup candidate for VL.
A larger scale synthesis of R-6 has recently provided a single 170 g batch of high-quality material (HPLC purity of >99.9% and 97.2% ee) in reasonable overall yield (8% over nine linear 
Article steps, starting from commercial R-solketal). However, the current synthetic route would still require significant improvement to deliver a scalable, robust, and cost-effective chemical process, in line with the stated TPP objectives for an affordable drug. Possible alternatives include using the known 56 enantiomer of orthogonally diprotected triol 125 and following the pathway described for S-6 in Scheme 4B because this enantiomer could be obtained from the cheap, optically pure starting material D-mannitol (via the less expensive Ssolketal). 57 Mechanistic studies of the closely related nitroimidazooxazine R-1 demonstrated that it was not activated by the previously identified type I nitroreductase (NTR1) in Leishmania, which mediates the cidal effects of monocyclic nitroheterocyclic drugs such as fexinidazole and nifurtimox. 38, 58 Instead, the activity of R-1 was solely triggered by the same novel flavin mononucleotide-dependent NADH oxidoreductase (NTR2) in Leishmania that was employed by nitroimidazooxazoles, such as 4 and 5.
27 This new mode of action was elucidated through a combination of quantitative proteomics and whole genome sequencing of susceptible and drug resistant L. don promastigotes, the latter being generated via culture in the continuous presence of R-1 for 80 days (leading to a reduced level of expression of NTR2). 27 The further observation that R-1 and fexinidazole sulfone displayed additive effects against drug susceptible L. don sparked the suggestion of combination therapy between monocyclic and bicyclic nitro drugs to reduce the likelihood of any future clinical drug resistance. 38 However, we consider that it may be more preferable to look for alternative partner drugs for 3 (or R-6) with greater diversity in their mechanism of action.
One final aspect to consider with R-6 was its efficacy against a wider range of VL and cutaneous leishmaniasis (CL) strains. Overall, R-6 displayed potent broad-spectrum activity against both reference strains and clinical isolates (Table 9) These data confirm that R-6 has excellent potential as a therapy for VL and may have an additional application for the treatment of CL (the more common skin lesion form of leishmaniasis). 1 SAR of 6-Substituted 2-Nitroimidazo(or 2-Nitrotriazolo)oxazines for Chagas Disease. While the primary objective of this reinvestigation of pretomanid analogues was to develop a backup drug candidate for VL, retrospective screening against the protozoan parasites T. cruzi and T. brucei presented an opportunity to assess the possible capacity of these compounds to treat Chagas disease and human African trypanosomiasis (HAT), respectively. A brief inspection of Tables 1−4 found that only one compound (116) had submicromolar activity against HAT (T. brucei IC 50 of 0.63 μM), and this hit could be disregarded on the basis of its less favorable mouse PK profile, inferior aqueous solubility, and 
Article poor MDCK-MDR1 cell permeability. 36 Conversely, like 7-substituted 2-nitroimidazooxazines, 24 the majority of compounds displayed interesting potencies against T. cruzi (IC 50 s of 0.025−1 μM). The selective anti-Chagas activity of nitrotriazolooxazines (e.g., 49; T. cruzi IC 50 of 0.25 μM vs >64 μM against L. inf) was particularly striking, being reminiscent of that of a nitrotriazolooxazole analogue of 4.
25 However, further scrutiny revealed that the enantiomers of 48 were roughly equipotent (Table 3) , while the racemic nitrotriazole counterparts of key VL leads R-6, R-84, and R-136 (47, 88, and 139, respectively) were 9−68-fold less active, suggesting limited utility for this class.
Aside from the less suitable reversed linker congeners (24− 26, 116, and 117) and O-linked biaryls (R-157, R-160, R-161, R-168, and R-171), the most potent 6-substituted 2-nitroimidazooxazine anti-Chagas leads were para-linked phenylpyridines (e.g., R-84, R-89, R-90, R-92, and R-93; IC 50 s of 0.025−0.078 μM). Here, the 6R enantiomers were clearly superior (by 15-to >400-fold), and the 2-pyridine isomer was preferred, although N-oxidation of the pyridine ring (R-85) was strongly deactivating (77-fold). In the monoaryl subset, arylpropargyl ether R-122 and phenyl ether R-6 seemed highly promising (IC 50 s of 0.11 and 0.15 μM, respectively), with the latter favored on PK and solubility grounds, whereas similarly active benzylamines R-148 and R-149 were expected to show rapid metabolism. 36 Overall, given the significant hERG liability and higher level of plasma protein binding of the phenylpyridines (e.g., 97.9% for R-84 in mice), R-6 was also regarded as the best new lead for Chagas disease, although its mechanism of action for this application remains to be determined.
■ CONCLUSIONS
In response to a compelling clinical need for more satisfactory VL treatments, recent efforts have been made to reposition leads from other therapeutic areas, seeking to accelerate new drug development. Promising results with antitubercular nitroimidazooxazoles and 7-substituted 2-nitroimidazooxazines encouraged us to evaluate additional scaffolds, e.g., nitroimidazooxazepines and methylated or reversed C-6 linker analogues of pretomanid, but these lacked sufficient potency and/or suitable PK and efficacy in the L. don mouse model. However, phenotypic screening of our pretomanid analogue library and follow-up IC 50 testing unveiled more active hits spanning a wide lipophilicity range (CLogP values of 1.2−4.5), including several with better solubility and microsomal stability, e.g., phenylpyridines and benzamide S-151. This work also pointed to the generally improved activities of novel 6R enantiomers, which was confirmed for phenylpyridines through comparative appraisal in the mouse VL model. Further studies in this series established that a 4-trifluoromethoxy phenyl substituent, para linkage, and a proximal 2-pyridine ring were preferred for good in vivo PK and efficacy, with two such leads (R-84 and R-89) giving ≥99% parasite clearance in the L. inf hamster model at 50 mg/kg b.i.d. These compounds also showed high potencies against T. cruzi, but unexpectedly high levels of hERG inhibition ultimately terminated their development.
Meanwhile, investigation of the C-6 linker group revealed that the parent ether moiety in R-1 (OCH 2 ) was nonoptimal for VL, with shorter and longer chain variants (O and OCH 2 CC, respectively) improving potency against L. inf (whereas O-carbamate and N-linked alternatives were poor). Although O-linked phenylpyridine R-168 displayed superb activity in the mouse VL model (99.7% reduction in parasite burden at 6.25 mg/kg, similar to the case for 4), we elected to focus instead on two less lipophilic monoaryl leads (R-6 and pyridine R-136), having superior solubility values (12−110 μg/ mL), low hERG risk, and excellent PK profiles in three species (mouse, rat, and hamster). Both compounds delivered high efficacies in the chronic infection hamster model (≥97% inhibition at 25 mg/kg, b.i.d.) and showed weakened binding to plasma proteins, although a positive Ames test for pyridine R-136 dissuaded its further advancement and earmarked R-6 as the favored VL backup candidate to 3. Finally, like the phenylpyridines, R-6 also demonstrated interesting activity against T. cruzi, whereas nitrotriazolooxazine congeners of such leads were less effective. These results provide new insights into the exciting potential of bicyclic nitroimidazoles as novel therapies for the treatment of some challenging neglected diseases.
■ EXPERIMENTAL SECTION
Combustion analyses were performed by the Campbell Microanalytical Laboratory, University of Otago, Dunedin, New Zealand. Melting points were determined using an Electrothermal IA9100 melting point apparatus and are as read. NMR spectra were measured on a Bruker Avance 400 spectrometer at 400 MHz for 1 H and 100 MHz for 13 C and were referenced to Me 4 Si or solvent resonances. Chemical shifts and coupling constants were recorded in units of parts per million and hertz, respectively. High-resolution electron impact (HREIMS), chemical ionization (HRCIMS), and fast atom bombardment (HRFABMS) mass spectra were recorded on a VG-70SE mass spectrometer at a nominal 5000 resolution. High-resolution electrospray ionization (HRESIMS) mass spectrometry was conducted on a Bruker micrOTOF-Q II mass spectrometer. Low-resolution atmospheric-pressure chemical ionization (APCI) mass spectra were obtained for organic solutions using a ThermoFinnigan Surveyor MSQ mass spectrometer connected to a Gilson autosampler. Optical rotations were measured on a Schmidt + Haensch Polartronic NH8 polarimeter. Column chromatography was performed on silica gel (Merck 230−400 mesh). Chromatographed compounds were typically further purified by crystallization from two solvent combinations, e.g., CH 2 Cl 2 and n-hexane, EtOAc and n-hexane, Et 2 O and n-pentane, or CH 2 Cl 2 and n-pentane (occasionally, Et 2 O was added to the latter combination to induce solidification, while some compounds required cooling at −20°C); more polar compounds were first dissolved in a minimum of 10% MeOH/CH 2 Cl 2 and slowly diluted with n-hexane to give the solid product. Thin-layer chromatography was performed on aluminum-backed silica gel plates (Merck 60 F 254 ), with visualization of components by UV light (254 nm), I 2 , or KMnO 4 staining. Tested compounds (including batches screened in vivo) were all ≥95% pure, as determined by combustion analysis (results within 0.4% of theoretical values) and/or by HPLC conducted on an Agilent 1100 system with diode array detection, using a 150 mm × 3.2 mm Altima 5 μm reversed phase C18 column or a 150 mm × 4.6 mm Zorbax Eclipse XDB 5 μm C8 column and eluting with a gradient (40 to 100%) of 80% CH 3 CN/water in 45 mM ammonium formate buffer (pH 3.5). Finally, the chiral purity of lead R-6 was assessed by HPLC performed on a Shimadzu 2010 system with diode array detection, employing a 150 mm × 4.6 mm CHIRALPAK AY-H 5 μm analytical column and isocratic elution with 20% EtOH/n-heptane.
Compounds of (11) . A mixture of alcohol 10 (248 mg, 0.688 mmol), 3,4-dihydro-2H-pyran (0.32 mL, 3.51 mmol), and PPTS (95 mg, 0.378 mmol) in anhydrous CH 2 Cl 2 (10 mL) under N 2 was stirred at 20°C for 5 h. The resulting solution was diluted with CH 2 Cl 2 (100 mL) and washed with aqueous NaHCO 3 (2 × 50 mL), water (50 mL), and brine (50 mL), backextracting with CH 2 Cl 2 (50 mL). The combined extracts were dried (Na 2 SO 4 ) and then evaporated to dryness under reduced pressure, and the remaining oil was chromatographed on silica gel. Elution with 10% EtOAc/petroleum ether gave 11 (234 mg, 76%) as a yellow oil (a 1:1 mixture of diastereomers): (14) . A solution of alcohol 13 (50.7 mg, 0.255 mmol) and 4-(trifluoromethoxy)benzyl bromide (65 μL, 0.406 mmol) in anhydrous DMF (3 mL) under N 2 was treated with 60% NaH (20 mg, 0.50 mmol), and the mixture was stirred at 20°C for 3 h. The resulting mixture was diluted with EtOAc (150 mL) and washed with aqueous NaHCO 3 (50 mL), water (2 × 50 mL), and brine (50 mL), back-extracting with EtOAc (100 mL). The combined extracts were dried (Na 2 (36) . Reaction of silyl ether 35 with TBAF (1.1 equiv), using procedure C for 3 h (extracting the product five times with EtOAc), followed by chromatography of the product on silica gel, eluting with 33% EtOAc/petroleum ether (forerunners) and then with 33−50% EtOAc/petroleum ether, gave 36 (91%) as a white solid (37) . A solution of alcohol 36 (730 mg, 2.00 mmol) in anhydrous DMF (8 mL) under N 2 at 0°C was treated with 60% NaH (148 mg, 3.70 mmol) and then quickly degassed and resealed under N 2 . The mixture was stirred at 20°C for 3.5 h and then cooled to −78°C (CO 2 /acetone), the reaction quenched with ice/aqueous NaHCO 3 (50 mL), and the mixture extracted with EtOAc (7 × 50 mL). The extracts were washed with brine (50 mL) and then evaporated to dryness under reduced pressure (at 30°C), and the residue was chromatographed on silica gel. Elution with 0−33% EtOAc/petroleum ether first gave forerunners, and then further elution with 50% EtOAc/petroleum ether gave the crude product, which was chromatographed again on silica gel. Elution with 0−2% EtOAc/CH 2 Cl 2 first gave forerunners, and then further elution with 3−4% EtOAc/CH 2 Cl 2 gave 37 (144 mg, 25%) as a white solid: mp (CH 2 Cl 2 /hexane) 158−160°C; (41) . A mixture of alcohol 38 (51.0 mg, 0.256 mmol) and 4-(trifluoromethoxy)benzyl bromide (0.205 mL, 1.28 mmol) in anhydrous DMF (1.5 mL) under N 2 at 0°C was treated with 60% NaH (17.5 mg, 0.438 mmol) and then quickly degassed and resealed under N 2 . The mixture was stirred at 20°C for 130 min and then cooled to −78°C (CO 2 /acetone), the reaction quenched with ice/ aqueous NaHCO 3 (10 mL), and the mixture added to brine (40 mL) and extracted with CH 2 Cl 2 (5 × 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30°C), and the residue was chromatographed on silica gel. Elution with 0−50% EtOAc/petroleum ether first gave forerunners, and then further elution with 50% EtOAc/petroleum ether gave 39 (37 mg, 39%) as a white solid: mp (CH 2 Table 2 . The following section details the syntheses of compounds R-58 and R-69 of Table 2 , via representative procedures and key intermediates, as described in Scheme 2. For the syntheses of the other compounds in Table 2 , see the Supporting Information.
Synthesis of R-58 (Scheme 2A)
32 (56) with 2-iodobenzyl chloride (3.0 equiv) and NaH (1.6 equiv), using procedure G for 3. Procedure H:
. A mixture of iodide 57 (435 mg, 1.08 mmol), [4-(trifluoromethoxy) phenyl]boronic acid (401 mg, 1.95 mmol), and Pd(dppf)Cl 2 (56 mg, 0.077 mmol) in DMF (6 mL) and aqueous KHCO 3 (2 mL of a 2 M solution, 4.0 mmol) was degassed, and then N 2 was added. The resulting mixture was stirred at 75°C for 4 h, and then cooled, diluted with brine (100 mL), and extracted with CH 2 Cl 2 (3 × 100 mL). The extracts were evaporated to dryness under reduced pressure, and the residue was chromatographed on silica gel. Elution with CH 2 Cl 2 first gave forerunners, and then further elution with 2% MeOH/CH 2 Cl 2 gave R-58 (218 mg, 46%) as a cream solid: mp (CH 2 32 with 2-bromo-3-(bromomethyl)pyridine (66) (1.6 equiv) and NaH (1.6 equiv), using procedure G at 0°C for 1 h and then at 20°C for 80 min, followed by chromatography of the product on silica gel, eluting with 0−0.5% MeOH/CH 2 Compounds of Table 3 . The following section details the syntheses of compounds R-122, R-136, R-140, R-147, R-151, and R-155 of Table 3 , via representative procedures and key intermediates, as described in Schemes 4 and 5. For the syntheses of the other compounds in Table 3 32 (430 mg, 2.32 mmol) and (3-bromoprop-1-yn-1-yl)(tert-butyl)dimethylsilane 41 (120) (900 mg, 3.86 mmol) in anhydrous DMF (6 mL) under N 2 was treated with 60% NaH (148 mg, 3.70 mmol), and the mixture was stirred at 20°C for 15 min. The resulting mixture was diluted with water (100 mL), and the precipitate was collected by filtration, washed with water and petroleum ether, and dried. This solid was then redissolved in THF (10 mL); TBAF (6.0 mL of a 1 M solution in THF, 6.0 mmol) was added, and the mixture was stirred at 20°C for 30 min. The resulting mixture was diluted with EtOAc (100 mL) and washed with water (2 × 100 mL) and brine (100 mL), back-extracting with EtOAc (100 mL). The combined extracts were dried (Na 2 SO 4 ) and then evaporated to dryness under reduced pressure, and the residue was chromatographed on silica gel. Elution with 50% EtOAc/petroleum ether first gave forerunners, and then further elution with EtOAc gave 121 (312 mg, 60%) as a 
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Article 0.01 mmol) in triethylamine (5 mL) and DMF (5 mL) was purged with N 2 . Pd(PPh 3 ) 2 Cl 2 (7 mg, 0.01 mmol) was added, and the mixture was stirred at 70°C for 15 min under N 2 and then cooled, diluted with water (100 mL), and extracted with EtOAc (2 × 100 mL). The extracts were combined and evaporated to dryness under reduced pressure, and the residue was chromatographed on silica gel. Elution with 50% EtOAc/petroleum ether first gave forerunners, and then further elution with EtOAc gave R-122 ( (20 mL) under N 2 at −10°C was treated with 60% NaH (275 mg, 6.88 mmol), then quickly degassed, and resealed under N 2 . Then 2-fluoro-5-(trifluoromethyl)pyridine (1.32 g, 8.00 mmol) was added, and the mixture was stirred at −10 to 0°C for 1 h. Additional 2-fluoro-5-(trifluoromethyl)pyridine (450 mg, 2.73 mmol) was added, and the mixture was stirred at 20°C for 130 min. The resulting mixture was cooled to −78°C (CO 2 /acetone), the reaction quenched with ice/aqueous NaHCO 3 (20 mL), and then the mixture added to brine (100 mL) and extracted with CH 2 Cl 2 (7 × 100 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30°C), and the residue was chromatographed on silica gel. Elution with CH 2 Cl 2 first gave forerunners, and then further elution with 0−2% EtOAc/CH 2 Cl 2 gave the product, which was triturated in Et 2 O (10 mL) and diluted with pentane (90 mL) to give R-136 (1. and AcOH (65 μL, 1.14 mmol) in anhydrous DMF (5 mL) under N 2 . The mixture was stirred at 20°C for 15 min and then cooled to 0°C. Sodium cyanoborohydride (73 mg, 1.16 mmol) was added, and the mixture was quickly degassed and resealed under N 2 and then stirred at 20°C for 7 h. The resulting mixture was cooled to −78°C (CO 2 /acetone), the reaction quenched with ice/aqueous Na 2 CO 3 (10 mL), and the mixture added to brine (40 mL) and extracted with CH 2 Cl 2 (6 × 50 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30°C), and the residue was chromatographed on silica gel. Elution with 0−0.25% MeOH/CH 2 (50 mL) under N 2 at 20°C (water bath cooling). After being stirred at 20°C for 41 h, the mixture was concentrated under reduced pressure (at 25°C), and the residual oil was added to excess petroleum ether (100 mL) at the top of a silica gel column (50 g The resulting cooled mixture was added to aqueous NaHCO 3 (100 mL) and extracted with CH 2 Cl 2 (6 × 100 mL). The combined extracts were evaporated to dryness under reduced pressure (at 30°C), and the residue was chromatographed on silica gel. Elution with 0−30% EtOAc/petroleum ether first gave forerunners, and then further elution with 30−50% EtOAc/petroleum ether gave 165 2 Cl 2 (175 mL) was stirred at 20°C for 48 h. Additional DDQ (202 mg, 0.89 mmol) was added, and stirring was continued at 20°C for 50 h. The resulting mixture was added to saturated aqueous NaHCO 3 (200 mL) and extracted with CH 2 Cl 2 (4 × 150 mL). The extracts were sequentially washed with aqueous NaHCO 3 (150 mL); then the combined extracts were evaporated to dryness under reduced pressure (at 30°C), and the remaining oil was chromatographed on silica gel. Elution with CH 2 Cl 2 first gave forerunners, and then further elution with 3% MeOH/CH 2 Cl 2 gave the crude product mixture (4.09 g) as a pale yellow foam. This material was suspended in 3:1 MeOH/CH 2 Cl 2 (200 mL) and treated with p-toluenesulfonic acid monohydrate (0.79 g, 4.15 mmol), stirring at 20°C for 10 h. Excess NaHCO 3 (0.5 g) was added, and the mixture was concentrated under reduced pressure, then diluted with aqueous NaHCO 3 (100 mL), and extracted with CH 2 Cl 2 (5 × 100 mL). The combined extracts were evaporated to dryness under reduced pressure, and the remaining oil was chromatographed on silica gel. Elution with 0−1% MeOH/CH 2 Cl 2 first gave forerunners, and then further elution with 1−2% MeOH/CH 2 (50 mL) under N 2 at 0°C was treated with 60% NaH (419 mg, 10.5 mmol) and then quickly degassed and resealed under N 2 . The mixture was stirred at 0°C for 45 min and then at 20°C for 160 min, then cooled to −78°C (CO 2 /acetone), the reaction quenched with ice/aqueous NaHCO 3 (20 mL), and the mixture added to brine (200 mL). The resulting mixture was sequentially extracted with CH 2 Cl 2 (150 mL), 10% MeOH/CH 2 Cl 2 (4 × 150 mL), 20% EtOAc/CH 2 Cl 2 (4 × 150 mL), 25% MeOH/ CH 2 Cl 2 (4 × 150 mL), CH 2 Cl 2 (2 × 150 mL), and EtOAc (150 mL), and then the combined extracts were evaporated to dryness under reduced pressure (at 30°C). The crude residue was triturated in water, filtered and dried, then resuspended in warm 5% MeOH/CH 2 Cl 2 (100 mL), cooled, and filtered to give 167 (1.93 g, 73%) The filtrate described above was evaporated to dryness under reduced pressure, and the residue was chromatographed on silica gel. Elution with 0−0.5% MeOH/CH 2 Cl 2 first gave forerunners, and then further elution with 0.5−0.67% MeOH/CH 2 Cl 2 gave the crude product, which was suspended in warm 10% MeOH/CH 2 Cl 2 (15 mL), then diluted with CH 2 Cl 2 (20 mL) and hexane (50 mL), and filtered to give additional 167 (233 mg, 9%). Minimum Inhibitory Concentration Assays (MABA and LORA). These assays against M. tb were performed according to the reported procedures. 59, 60 Results in Table 1 are the mean of two or three independent determinations (SD data are given in Table S1 ).
In Vitro Parasite Growth Inhibition Assays. The activity of test compounds against the amastigote stage of the L. don parasite was measured at CDRI using a mouse macrophage-based luciferase assay, performed according to the published procedures. 26 Replicate assays quantifying the growth inhibitory action of compounds against L. inf, T. cruzi, and T. brucei and assessing any cytotoxic effects on human lung fibroblasts (MRC-5 cells) were conducted at the University of Antwerp (LMPH), as previously described; 44 results in Tables 1−4 are the mean of at least two (up to 10) independent determinations (SD data are given in Tables S1−S4). Additional assays using a wider range of VL and CL strains and clinical isolates were performed via comparable methods at LMPH 44 or LSHTM 26 (primary peritoneal mouse macrophages infected with cultured promastigotes were incubated at 37°C for 24 h prior to the addition of test compounds and then further incubated for either 3 or 5 days for CL or VL assays, respectively).
Solubility Determinations. Method A. The solid compound sample was mixed with water or 0.1 M HCl (enough to make a 2 mM solution) in an Eppendorf tube, and the suspension was sonicated for 15 min and then centrifuged at 13000 rpm for 6 min. An aliquot of the clear supernatant was diluted 2-fold with water (or 0.1 M HCl), and then HPLC was performed (as described). The kinetic solubility was calculated by comparing the peak area obtained with that from a standard solution of the compound in DMSO (after allowing for varying dilution factors and injection volumes).
Method B. The thermodynamic solubility of compound R-6 at pH 7.4 was measured by Syngene International Ltd. (Plot No. 2 and 3 Biocon Park, Jigani Link Road, Bangalore 560099, India). The dry powder was equilibrated with 0.1 M phosphate buffer (pH 7.4) in a glass vial at 25°C (water bath), shaking for 24 h. After filtration using a 0.45 μm PVDF membrane filter, the concentration of R-6 was determined by HPLC (Waters e2695 system, employing a 150 mm × 4.6 mm XBridge 3.5 μm reversed phase C18 column and isocratic elution with 50% CH 3 CN in 10 mM ammonium acetate buffer, at 1 mL/min), comparing the peak area obtained with that from a standard solution (0.93 mM) in 1:1:2 EtOH/water/CH 3 CN.
Microsomal Stability Assays. Compound 22 was tested by MDS Pharma Services (22011 30th Dr. SE, Bothell, WA 98021-4444), as described previously. 47 Studies of compounds 24, S-51, S-77, R-77, S-81, R-81, R-84, S-89, R-89, S-91, R-91, S-92, R-92, R-94, 116, 117, S-151, and S-155 (Table 5) Distribution Coefficient. This was measured by WuXi AppTec (Shanghai) Co., Ltd. The LogD value of R-6 was found by assessing its distribution between 100 mM phosphate buffer (pH 7.4) and octanol at room temperature (final matrix contained 1% DMSO), using the shake-flask method and LC−MS/MS analysis.
Permeability Assay. The assay was performed by WuXi AppTec (Shanghai) Co., Ltd. MDCK-MDR1 cells were seeded onto polyethylene membranes in 96-well plates at a density of 2 × 10 5 cells/cm 2 , giving confluent cell monolayer formation over 4−7 days. A solution of R-6 (2 μM in 0.4% DMSO/HBSS buffer) was applied to the apical or basolateral side of the cell monolayer. Permeation of the compound in the A to B direction or B to A direction was assessed in triplicate over a 150 min incubation at 37°C and 5% CO 2 (95% humidity). In addition, the efflux ratio of R-6 was also determined. Test and reference compounds were quantified by LC−MS/MS analysis based on the peak area ratio of the analyte/internal standard.
Plasma Protein Binding Assays. The studies of 4 and R-6 were performed by WuXi AppTec (Shanghai) Co., Ltd., using equilibrium dialysis across a semipermeable membrane. Briefly, 2 μM compound solutions in plasma were dialyzed against 100 mM phosphate-buffered saline (pH 7.4) on a rotating plate (150 rpm) incubated at 37°C for 4 or 6 h. Following precipitation of protein with CH 3 CN, the amount of compound present in each compartment was quantified by LC−MS/ MS; values are the mean of triplicate determinations.
Ames Test. Compounds R-6 and R-136 (at doses of 1.5, 4, 10, 25, 64, 160, 400, and 1000 μg/well) were evaluated in triplicate in the Mini-Ames reverse mutation screen conducted by WuXi AppTec (Suzhou) Co., Ltd. (1318 Wuzhong Ave., Wuzhong District, Suzhou 215104, China). Two strains of Salmonella typhimurium (TA98 and TA100) were employed, in the presence and absence of metabolic activation (rat liver S9). Positive controls (2-aminoanthracene, 2-nitrofluorene, and sodium azide) and a negative (DMSO solvent) control were included.
hERG Assay. The effects of compounds R-6, R-84, R-89, and R-136 on cloned hERG potassium channels expressed in Chinese hamster ovary cells were assessed by WuXi AppTec (Shanghai) Co., Ltd., using the automated patch clamp method. Six concentrations (0.12, 0.37, 1.11, 3.33, 10, and 30 μM) were tested (at room temperature), and at least three replicates were obtained for each.
CYP3A4 Inhibition Assay. This work was performed by WuXi AppTec (Shanghai) Co., Ltd. Compound R-6 (at concentrations of 1 and 10 μM) was incubated with NADPH-fortified pooled HLM (0.2
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